TMS (Transcranial Magnetic Stimulation) is a neurostimulation technique that uses magnetic field generators (in the form of coils) to emit targeted electrical currents that stimulate the cortex. TMS is believed to improve neurological functioning via stimulating activity in hypoactive regions of the brain that are contributing to a particular pathology. For example, individuals with depression …
According to the World Health Organization (WHO), depression is projected to become the number one global disease burden by 2030. Present-day statistics suggest that depression affects over 350 million people worldwide. Among those who are depressed, seeking professional psychiatric treatment is often helpful. An estimated 66% of all individuals who seek treatment are able to …
Most pharmacological-based treatments for depression aim to increase levels of various neurotransmitters, particularly serotonin (5-HT). It is thought that approximately 2 out of 3 individuals that seek treatment with standard antidepressants such as SSRIs and SNRIs are able to attain therapeutic relief. For a certain percentage of these individuals, the benefits of using pharmaceutical interventions …
We all know that getting enough sleep promotes healthy brain function and optimal cognitive performance. Most sources recommend getting approximately 8 hours of sleep per night, but the amount of sleep it takes for you to feel refreshed should be individualized. Someone who is training for a marathon will generally need more sleep (over 8 …
Invega (Paliperidone) is considered a newer spin-off of the antipsychotic Risperdal in that it contains the same active metabolite, but is thought to have fewer side effects and drug interactions. It was initially approved in 2006 for the treatment of schizophrenia and was since granted approval for the treatment of schizoaffective disorder in 2009. While …
Invega (Paliperidone) is an atypical antipsychotic approved in 2006 for the treatment of schizophrenia. Several years later in 2009, a longer-acting format of the medication called “Invega Sustenna” was also approved. Invega Sustenna is an injectable form of the drug that is administered every 4 weeks and is thought to be advantageous it mitigates risk …
Fanapt (Iloperidone) is an antipsychotic that was approved in 2009 for the treatment of schizophrenia. It functions similar to most current-market atypical antipsychotics in that it acts as an antagonist of the 5-HT2A receptor and D2 dopamine receptor. It is thought to produce fewer extrapyramidal side effects (e.g. akathisia) compared to other antipsychotics. The drug …